Tenderwize
Zurück zur Suche

Open-house biologics rebate agreement for Triptorelin embonate

Techniker Krankenkasse·Hamburg, Germany·Deadline Sep 29, 2027 · 401 days left·Open·Supplies
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-22 - Triptorelin embonat

46/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Warum diese Bewertung?

Chance

46 / 100

Komplexität

58 / 100

Risikofaktoren

Offers/contracts cannot be submitted through the portal; they must be sent by email with qualified electronic signature...

Participation is limited to pharmaceutical entrepreneurs meeting AMG seat and authorisation requirements for the releva...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Sep 2027
  • Conclusion of pharmaceutical rebate agreements under Section 130a(8) SGB V for the active substance Triptorelin embonate.
  • Open-house model with uniform terms for all suitable pharmaceutical companies; no individual contract negotiations.
Vollständige Zusammenfassung anzeigen

Open-house pharmaceutical supply arrangement in Germany for Triptorelin embonate (CPV 33600000) led by Techniker Krankenkasse with hkk and HEK as participating buyers. The procedure is non-exclusive, with no individual negotiations and open accession possible throughout the contract period. The contract term runs from 01.10.2025 to 30.09.2027 at the latest, with automatic earlier end if patent/market exclusivity expires. No contract value is stated. Procurement documents are available via the portal, but only the notice/XML text was analyzed, not the full documents.

Risiken

Offers/contracts cannot be submitted through the portal; they must be sent by email with qualified electronic signature...

Participation is limited to pharmaceutical entrepreneurs meeting AMG seat and authorisation requirements for the releva...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Applicant must be a pharmaceutical entrepreneur within the meaning of Section 4(18) AMG for the relevant medicinal product.
  • Applicant must have its registered seat in the AMG territory, another EU Member State, or another EEA state.
  • Applicant must hold a valid marketing authorisation for the relevant medicinal product or otherwise be entitled to place it on the market in its own name.

Auftraggeber

Ort

Hamburg, DEU

Kennung

992-80116-93

Tätigkeit

Health

Lose (1)

LOT-0001

Open-house biologics rebate agreement for Triptorelin embonate

Open-house agreement for pharmaceutical rebate contracts concerning the active substance Triptorelin embonate. Scope is nationwide in Germany and the arrangement is non-exclusive, with uniform conditions and no individual negotiations. The lot information comes from structured data and the XML notice.

SuppliesEU fundedElectronic submission

Ort

DE600, Germany

Dauer

Sep 2025 - Sep 2027

Kategorie

Pharmaceutical products

Frist

Deadline Sep 29, 2027

Vergabedetails

Veröffentlichungsdatum
07 Aug 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
521224-2025

Dokumente (1)

Vergabedokument 1

Ähnliche Ausschreibungen

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3